v3.26.1
Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 31, 2026
Accounting Policies [Abstract]  
Schedule of Disaggregation of Revenue by Major Source
The following table disaggregates our revenue by major source (in millions):
 Three Months Ended March 31,
 20262025
Automotive sales$15,473 $12,925 
Automotive regulatory credits380 595 
Energy generation and storage sales2,305 2,621 
Services and other3,745 2,638 
Total revenues from sales and services21,903 18,779 
Automotive leasing381 447 
Energy generation and storage leasing103 109 
Total revenues$22,387 $19,335 
Schedule of Sales-type and Direct Financing Leases, Lease Receivables, Gross Difference
Lease receivables relating to sales-type leases are presented on the consolidated balance sheets as follows (in millions):
 March 31, 2026December 31, 2025
Gross lease receivables$205 $259 
Unearned interest income(10)(14)
Allowance for expected credit losses(4)(5)
Net investment in sales-type leases$191 $240 
Reported as:
Prepaid expenses and other current assets$116 $130 
Other non-current assets75 110 
Net investment in sales-type leases$191 $240 
Schedule of Net Income per Share of Common Stock Attributable to Common Stockholders
Restricted stock awards will be excluded from the computation of diluted weighted average shares until the shares have been deemed to be earned. The following table presents the reconciliation of basic to diluted weighted average shares used in computing net income per share of common stock attributable to common stockholders (in millions):
Three Months Ended March 31,
20262025
Weighted average shares used in computing net income per share of common stock, basic3,2343,218
Add: Stock-based awards304303
Weighted average shares used in computing net income per share of common stock, diluted3,5383,521
Schedule of Potentially Dilutive Shares that were Excluded from Computation of Diluted Net Income per Share of Common Stock
The following table presents the potentially dilutive shares that were excluded from the computation of diluted net income per share of common stock attributable to common stockholders, because their effect was anti-dilutive (in millions):
Three Months Ended March 31,
20262025
Stock-based awards713
Schedule of Cash and Cash Equivalents and Restricted Cash
Our total cash and cash equivalents and restricted cash, as presented in the consolidated statements of cash flows, was as follows (in millions):
 March 31,
2026		December 31,
2025		March 31,
2025		December 31,
2024
Cash and cash equivalents$16,603 $16,513 $16,352 $16,139 
Restricted cash included in prepaid expenses and other current assets327 389 415 494 
Restricted cash included in other non-current assets725 714 483 404 
Total as presented in the consolidated statements of cash flows$17,655 $17,616 $17,250 $17,037 
Schedule of Accrued Warranty Activity
Accrued warranty activity consisted of the following (in millions):
Three Months Ended March 31,
20262025
Accrued warranty - beginning of period$8,607 $6,716 
Warranty costs incurred(468)(392)
Net changes in liability for pre-existing warranties, including expirations and foreign exchange impact(175)347 
Provision for warranty508 543 
Accrued warranty - end of period$8,472 $7,214